Acta Cytologica
Letter to the Editor
BRAF Mutations in Lung CancerPisapia P. · Pepe F. · Malapelle U. · Troncone G.Department of Public Health, University of Naples Federico II, Naples, Italy
|
|
Acta Cytologica 2019;63:247–250
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
* The final prices may differ from the prices shown due to specifics of VAT rules.
Article / Publication Details
Received: December 18, 2018
Accepted: December 21, 2018
Published online: March 06, 2019
Issue release date: May - June
Number of Print Pages: 4
Number of Figures: 2
Number of Tables: 2
ISSN: 0001-5547 (Print)
eISSN: 1938-2650 (Online)
For additional information: https://www.karger.com/ACY
First-Page Preview
Related Articles:
References
- Salimian KJ, Fazeli R, Zheng G, Ettinger D, Maleki Z. V600E BRAF versus non-V600E BRAF mutated lung adenocarcinomas: cytomorphology, histology, coexistence of other driver mutations and patient characteristics. Acta Cytol. 2018;62(2):79–84.
- Leonetti A, Facchinetti F, Rossi G, Minari R, Conti A, Friboulet L, et al. BRAF in non-small cell lung cancer (NSCLC): pickaxing another brick in the wall. Cancer Treat Rev. 2018 May;66:82–94.
- Lindeman NI, Cagle PT, Aisner DL, Arcila ME, Beasley MB, Bernicker EH, et al. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. Arch Pathol Lab Med. 2018 Mar;142(3):321–46.
- Kalemkerian GP, Narula N, Kennedy EB, Biermann WA, Donington J, Leighl NB, et al. Molecular testing guideline for the selection of patients with lung cancer for treatment with targeted tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology clinical practice guideline update. J Clin Oncol. 2018 Mar;36(9):911–9.
- Malapelle U, Mayo de-Las-Casas C, Rocco D, Garzon M, Pisapia P, Jordana-Ariza N, et al. Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients. Br J Cancer. 2017 Mar;116(6):802–10.
- De Luca C, Rappa AG, Gragnano G, Malapelle U, Troncone G, Barberis M. Idylla assay and next generation sequencing: an integrated EGFR mutational testing algorithm. J Clin Pathol. 2018 Aug;71(8):745–50.
Article / Publication Details
Received: December 18, 2018
Accepted: December 21, 2018
Published online: March 06, 2019
Issue release date: May - June
Number of Print Pages: 4
Number of Figures: 2
Number of Tables: 2
ISSN: 0001-5547 (Print)
eISSN: 1938-2650 (Online)
For additional information: https://www.karger.com/ACY
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
